Study of blood cancers’ natural course and next treatment needs
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old
- You have a diagnosis of CLL/SLL, or LPL/WM (a specific blood cancer type)
- For CLL/SLL: you are either already on treatment, previously treated, or getting close to needing first treatment
- For LPL/WM: your diagnosis must be confirmed with specific blood/bone marrow testing (immunophenotyping)
- You can do usual daily activities (ECOG status 0–2)
- You’re able to understand the study and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This study looks at how people with slow-growing lymphomas (like CLL, MZL, FL, or WM) feel during watchful waiting — when they are not on active treatment. It aims to see if patients are more anxious or worried, and how to best support them.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.